Kestra Medical Technologies reported fourth-quarter fiscal 2026 revenue of $28.6 million, a 66% increase driven by market share gains and expansion of the wearable cardioverter defibrillator category. Full-year revenue reached $95.1 million, up 59%, with gross margin expanding to 54.8% in the quarter and 51.4% for the year. The company wrote 6,357 prescriptions for its ASSURE system in Q4, a 63% jump, and ended the fiscal year with 130 sales territories, up from 80. Kestra guided for fiscal 2027 revenue of $137 million, representing 44% growth, and announced a new $200 million term loan facility with Pharmakon that reduces its cost of capital by 24% while providing total liquidity of $357 million.
Kestra Medical Technologies, Ltd. Common StockQ4 revenue up 66%, full-year up 59%, gross margin expansion, and FY2027 guidance of $137M (44% growth) plus a new $200M loan facility reducing cost of capital.